Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282204 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL2575225 | 1.00 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL4719490 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL13387564 | 0.93 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL30581344 | 0.90 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL16526220 | 0.88 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8260235 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8259162 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8257128 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL28019672 | 0.87 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220259154-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-2804851-B1 | LACTAM DERIVATES USEFUL AS INHIBITORS OF MUTANT IDH1 | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2663312-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012097013-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259154-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | GAA 1082/4885MAPK1 4010/4885HTT 2521/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | GAA 1082/4885MAPK1 4010/4885HTT 2521/4885 |
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | GAA 2082/4885MAPK1 416/4885HTT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.